Oxalic Acid

Oxalic Acid

SCHEMBL5212883

CN1CCC(C(=O)c2cccc(NC(=S)Nc3ccccc3C(F)(F)F)c2)CC1.O=C(O)C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1F P30939 1/20 0.54
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 4/20 0.46
MAPT P10636 3/20 0.46
ALOX12 P18054 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
POLB P06746 2/20 0.42
TSHR P16473 1/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
MEN1 O00255 1/20 0.42
PLA2G1B P04054 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5211892 0.88 HTR1F (0.48) HTR1FKMT2AALDH1A1MAPTALOX12
Oxalic Acid SCHEMBL5212893 0.87 HTR1F (0.58) HTR1FKMT2AALDH1A1MAPTALOX12
SCHEMBL5209513 0.85 HTR1F (0.65) HTR1FKMT2AALDH1A1ALOX12GAA
Oxalic Acid SCHEMBL27457318 0.84 HTR1F (0.60) HTR1FKMT2AALDH1A1POLBPKM
SCHEMBL5209959 0.84 HTR1F (0.62) HTR1FKMT2AALDH1A1MAPTGAA
SCHEMBL5212195 0.84 HTR1F (0.56) HTR1FKMT2APOLBTSHRMEN1
Acrylic Acid SCHEMBL5208516 0.84 HTR1F (0.52) HTR1FKMT2AALDH1A1MAPTPOLB
SCHEMBL5209076 0.83 HTR1F (0.58) HTR1FKMT2AALDH1A1MAPTGAA
SCHEMBL5211088 0.83 HTR1F (0.58) HTR1FKMT2AALDH1A1MAPTPOLB
SCHEMBL5212244 0.83 HTR1F (0.58) HTR1FKMT2AALDH1A1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1153013-B1 5-HT1F AGONISTS LILLY CO ELI (US) 2007-10-31 EP disclosed
US-20060178349-A1 Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID POZEN INC. (US) 2006-08-10 US disclosed
US-6777428-B1 INHIBIT PEPTIDE EXTRAVASATION DUE TO STIMULATION OF THE TRIGEMINAL GANGLIA, AND ARE THEREFORE USEFUL FOR THE TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS ELI LILLY AND COMPANY 2004-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178349-A1 Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID HTR1F, HTR1A, HTR1E HTR1F 1/4885KMT2A 3859/4885ALDH1A1 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.